292 related articles for article (PubMed ID: 23990115)
21. An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance.
Deng S; Krutilina RI; Wang Q; Lin Z; Parke DN; Playa HC; Chen H; Miller DD; Seagroves TN; Li W
Mol Cancer Ther; 2020 Feb; 19(2):348-363. PubMed ID: 31645441
[TBL] [Abstract][Full Text] [Related]
22. LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.
Lai H; Wang R; Li S; Shi Q; Cai Z; Li Y; Liu Y
Sci China Life Sci; 2020 Mar; 63(3):419-428. PubMed ID: 31420851
[TBL] [Abstract][Full Text] [Related]
23. Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases.
Kai K; Kondo K; Wang X; Xie X; Pitner MK; Reyes ME; Torres-Adorno AM; Masuda H; Hortobagyi GN; Bartholomeusz C; Saya H; Tripathy D; Sen S; Ueno NT
Mol Cancer Ther; 2015 Dec; 14(12):2687-99. PubMed ID: 26443806
[TBL] [Abstract][Full Text] [Related]
24. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
[TBL] [Abstract][Full Text] [Related]
25. Preclinical investigations with epothilones in breast cancer models.
Burris HA
Semin Oncol; 2008 Apr; 35(2 Suppl 2):S15-21; quiz S39. PubMed ID: 18410795
[TBL] [Abstract][Full Text] [Related]
26. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
[TBL] [Abstract][Full Text] [Related]
27. The aurora kinase inhibitor AMG 900 increases apoptosis and induces chemosensitivity to anticancer drugs in the NCI-H295 adrenocortical carcinoma cell line.
Borges KS; Andrade AF; Silveira VS; Marco Antonio DS; Vasconcelos EJR; Antonini SRR; Tone LG; Scrideli CA
Anticancer Drugs; 2017 Jul; 28(6):634-644. PubMed ID: 28410270
[TBL] [Abstract][Full Text] [Related]
28. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.
Chang CH; Bijian K; Wernic D; Su J; da Silva SD; Yu H; Qiu D; Asslan M; Alaoui-Jamali MA
Autophagy; 2019 Aug; 15(8):1376-1390. PubMed ID: 30773992
[TBL] [Abstract][Full Text] [Related]
29. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.
Shimomura T; Hasako S; Nakatsuru Y; Mita T; Ichikawa K; Kodera T; Sakai T; Nambu T; Miyamoto M; Takahashi I; Miki S; Kawanishi N; Ohkubo M; Kotani H; Iwasawa Y
Mol Cancer Ther; 2010 Jan; 9(1):157-66. PubMed ID: 20053775
[TBL] [Abstract][Full Text] [Related]
30. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
Burnett JP; Lim G; Li Y; Shah RB; Lim R; Paholak HJ; McDermott SP; Sun L; Tsume Y; Bai S; Wicha MS; Sun D; Zhang T
Cancer Lett; 2017 May; 394():52-64. PubMed ID: 28254410
[TBL] [Abstract][Full Text] [Related]
31. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer.
Gully CP; Zhang F; Chen J; Yeung JA; Velazquez-Torres G; Wang E; Yeung SC; Lee MH
Mol Cancer; 2010 Feb; 9():42. PubMed ID: 20175926
[TBL] [Abstract][Full Text] [Related]
32. Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells.
Kaneko N; Yamanaka K; Kita A; Tabata K; Akabane T; Mori M
Biol Pharm Bull; 2013; 36(12):1921-7. PubMed ID: 24432379
[TBL] [Abstract][Full Text] [Related]
33. Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer.
Zhao YQ; Yin YQ; Liu J; Wang GH; Huang J; Zhu LJ; Wang JH
Acta Pharmacol Sin; 2016 Sep; 37(9):1237-50. PubMed ID: 27397540
[TBL] [Abstract][Full Text] [Related]
34. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
35. MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib.
Young AI; Law AM; Castillo L; Chong S; Cullen HD; Koehler M; Herzog S; Brummer T; Lee EF; Fairlie WD; Lucas MC; Herrmann D; Allam A; Timpson P; Watkins DN; Millar EK; O'Toole SA; Gallego-Ortega D; Ormandy CJ; Oakes SR
Breast Cancer Res; 2016 Dec; 18(1):125. PubMed ID: 27931239
[TBL] [Abstract][Full Text] [Related]
36.
Liu H; Sun H; Zhang B; Liu S; Deng S; Weng Z; Zuo B; Yang J; He Y
Breast Cancer; 2020 May; 27(3):372-380. PubMed ID: 31781983
[TBL] [Abstract][Full Text] [Related]
37. Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis.
Doheny D; Sirkisoon S; Carpenter RL; Aguayo NR; Regua AT; Anguelov M; Manore SG; Arrigo A; Jalboush SA; Wong GL; Yu Y; Wagner CJ; Chan M; Ruiz J; Thomas A; Strowd R; Lin J; Lo HW
Oncogene; 2020 Oct; 39(42):6589-6605. PubMed ID: 32929154
[TBL] [Abstract][Full Text] [Related]
38. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
Qi W; Liu X; Cooke LS; Persky DO; Miller TP; Squires M; Mahadevan D
Int J Cancer; 2012 Jun; 130(12):2997-3005. PubMed ID: 21796626
[TBL] [Abstract][Full Text] [Related]
39. DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy.
Bernier C; Soliman A; Gravel M; Dankner M; Savage P; Petrecca K; Park M; Siegel PM; Shore GC; Roulston A
Anticancer Drugs; 2018 Sep; 29(8):774-785. PubMed ID: 29878901
[TBL] [Abstract][Full Text] [Related]
40. Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.
Diamond JR; Eckhardt SG; Tan AC; Newton TP; Selby HM; Brunkow KL; Kachaeva MI; Varella-Garcia M; Pitts TM; Bray MR; Fletcher GC; Tentler JJ
Clin Cancer Res; 2013 Jan; 19(1):291-303. PubMed ID: 23136197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
